Applicants,Chemical_Name,Funding_requested_for,Pharmaceutical,Priority_List,Schedules,Therapeutic_group
Amgen,Carfilzomib,"Multiple myeloma, relapsed or refractory, 2nd line",Carfilzomib,Options for investment,,Oncology Agents and Immunosuppressants
